CASP1 and myocardial infarction: In a multicenter, randomized, placebo-controlled trial, Astiawati et al. demonstrated that colchicine treatment was associated with significant reductions in N-terminal pro–B-type natriuretic peptide, caspase-1, transforming growth factor-β, and galectin-3 levels in patients with acute myocardial infarction, reflecting attenuation of post-infarction inflammatory and fibrotic activity, although no significant improvement in short-term echocardiographic parameters was observed [20].